Free tool
FAERS Monitor: Denavir
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020629 or its brand name (Denavir, Penciclovir). Reports on generic versions are filed under their own applications.
Reports
362
Serious
217
60% of reports
Hospitalization
93
Death reported
24
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective46
- headache31
- fatigue28
- pain26
- diarrhoea25
- hypertension22
- chronic kidney disease20
- cough20
- vomiting20
- anaemia18
- condition aggravated18
- nausea18
- back pain17
- anxiety16
- depression16
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 6 |
| 2006 | 11 |
| 2007 | 10 |
| 2008 | 6 |
| 2009 | 9 |
| 2010 | 10 |
| 2011 | 14 |
| 2012 | 10 |
| 2013 | 13 |
| 2014 | 8 |
| 2015 | 27 |
| 2016 | 49 |
| 2017 | 28 |
| 2018 | 31 |
| 2019 | 32 |
| 2020 | 20 |
| 2021 | 16 |
| 2022 | 18 |
| 2023 | 9 |
| 2024 | 8 |
| 2025 | 8 |
| 2026 | 11 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,797 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 20 | 15.3 | 10.0 | 254 |
| hypertensionSignal | 22 | 6.0 | 4.0 | 88 |
| anaemiaSignal | 18 | 5.5 | 3.5 | 62 |
| back painSignal | 17 | 4.3 | 2.7 | 40 |
| coughSignal | 20 | 4.1 | 2.7 | 45 |
| depressionSignal | 16 | 4.1 | 2.5 | 35 |
| condition aggravatedSignal | 18 | 3.4 | 2.2 | 29 |
| anxietySignal | 16 | 3.3 | 2.0 | 23 |
| headacheSignal | 31 | 2.9 | 2.1 | 37 |
| vomitingSignal | 20 | 2.5 | 1.6 | 16 |
| painSignal | 26 | 2.5 | 1.7 | 22 |
| diarrhoeaSignal | 25 | 2.3 | 1.5 | 17 |
| fatigueSignal | 28 | 2.1 | 1.5 | 15 |
| drug ineffectiveSignal | 46 | 2.0 | 1.5 | 24 |
| nausea | 18 | 1.3 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.